Furthermore, an additional study demonstrated that METTL2B serves as a prominent biomarker in gastric cancer and exhibits a strong correlation with unfavorable prognosis, thereby indicating the potential of METTL2B for assessing cancer progression [69]. The gene discussed is METTL2B; the disease is cancer.